Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

Abstract

Herpes simplex virus type-1 (HSV1) in which the neurovirulence factor ICP34.5 is inactivated has been shown to direct tumour-specific cell lysis in several tumour models. Such viruses have also been shown to be safe in Phase I clinical trials by intra-tumoral injection in glioma and melanoma patients.1,2,3 Previous work has used serially passaged laboratory isolates of HSV1 which we hypothesized may be attenuated in their lytic capability in human tumour cells as compared to more recent clinical isolates. To produce ICP34.5 deleted HSV with enhanced oncolytic potential, we tested two clinical isolates. Both showed improved cell killing in all human tumour cell lines tested compared to a laboratory strain (strain 17+). ICP34.5 was then deleted from one of the clinical isolate strains (strain JS1). Enhanced tumour cell killing with ICP34.5 deleted HSV has also been reported by the deletion of ICP47 by the up-regulation of US11 which occurs following this mutation.4,5 Thus to further improve oncolytic properties, ICP47 was removed from JS1/ICP34.5−. As ICP47 also functions to block antigen processing in HSV infected cells, this mutation was also anticipated to improve the immune stimulating properties of the virus. Finally, to provide viruses with maximum oncolytic and immune stimulating properties, the gene for human or mouse GM-CSF was inserted into the JS1/34.5−/47- vector backbone. GM-CSF is a potent immune stimulator promoting the differentiation of progenitor cells into dendritic cells and has shown promise in clinical trials when delivered by a number of means. Combination of GM-CSF with oncolytic therapy may be particularly effective as the necrotic cell death accompanying virus replication should serve to effectively release tumour antigens to then induce a GM-CSF-enhanced immune response. This would, in effect, provide an in situ, patient-specific, anti-tumour vaccine. The viruses constructed were tested in vitro in human tumour cell lines and in vivo in mice demonstrating significant anti-tumour effects. These were greatly improved compared to viruses not containing each of the modifications described. In vivo, both injected and non-injected tumours showed significant shrinkage or clearance and mice were protected against re-challenge with tumour cells. The data presented indicate that JS1/ICP34.5−/ICP47-/GM-CSF acts as a powerful oncolytic agent which may be appropriate for the treatment of a number of solid tumour types in man.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 2
Figure 1
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859–866.

    Article  CAS  PubMed  Google Scholar 

  2. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867–874.

    CAS  PubMed  Google Scholar 

  3. MacKie RM, Stewart B, Brown SM . Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525–526.

    Article  CAS  PubMed  Google Scholar 

  4. He B et al. Suppression of the phenotype of gamma(1)34.5− herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71: 6049–6054.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Mohr I et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189–5196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hawkins LK, Lemoine NR, Kirn D . Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002; 3: 17–26.

    Article  CAS  PubMed  Google Scholar 

  7. Ring CJ . Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491–502.

    Article  PubMed  Google Scholar 

  8. Fujiwara T, Kataoka M, Tanaka N . Adenovirus-mediated p53 gene therapy for human cancer. Mol Urol 2000; 4: 51–54.

    Article  CAS  PubMed  Google Scholar 

  9. Xu G, McLeod HL . Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314–3324.

    CAS  PubMed  Google Scholar 

  10. Belldegrun A et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12: 883–892.

    Article  CAS  PubMed  Google Scholar 

  11. Stewart AK et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 1999; 6: 350–363.

    Article  CAS  PubMed  Google Scholar 

  12. Ferrantini M, Belardelli F . Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol 2000; 10: 145–157.

    Article  CAS  PubMed  Google Scholar 

  13. Kaushik A . Leuvectin Vical Inc. Curr Opin Investig Drugs 2001; 2: 976–981.

    CAS  PubMed  Google Scholar 

  14. Chen Y et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453–5460.

    CAS  PubMed  Google Scholar 

  15. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–121.

    Article  CAS  PubMed  Google Scholar 

  16. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM . Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’equence. J Gen Virol 1991; 72: 631–639.

    Article  CAS  PubMed  Google Scholar 

  17. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938–943.

    Article  CAS  PubMed  Google Scholar 

  18. Yang CT et al. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61: 5959–5963.

    CAS  PubMed  Google Scholar 

  19. Chou J, Chen JJ, Gross M, Roizman B . Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5− mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516–10520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. He B, Gross M, Roizman B . The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997; 94: 843–848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lamont JP et al. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588–592.

    Article  CAS  PubMed  Google Scholar 

  22. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.

    CAS  PubMed  Google Scholar 

  23. Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798–806.

    CAS  PubMed  Google Scholar 

  24. Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8: 1618–1626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Todo T, Martuza RL, Rabkin SD, Johnson PA . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 2001; 98: 6396–6401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Taneja S et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804–8808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mohr I et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189–5196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–415.

    Article  CAS  PubMed  Google Scholar 

  29. Thompson RL et al. Functional and molecular analyses of the avirulent wild-type herpes simplex virus type 1 strain KOS. J Virol 1986; 58: 203–211.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Sedarati F, Stevens JG . Biological basis for virulence of three strains of herpes simplex virus type 1. J Gen Virol 1987; 68: 2389–2395.

    Article  CAS  PubMed  Google Scholar 

  31. Brown SM et al. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5−negative herpes simplex virus types 1 and 2. J Gen Virol 1994; 75: 2367–2377.

    Article  CAS  PubMed  Google Scholar 

  32. McMenamin MM et al. A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 1998; 83: 1225–1237.

    Article  CAS  PubMed  Google Scholar 

  33. Taneja S et al. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98: 8804–8808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Poppers J, Mulvey M, Khoo D, Mohr I . Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J Virol 2000; 74: 11215–11221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cassady KA, Gross M, Roizman B . The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 1998; 72: 8620–8626.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Tomazin R et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol 1998; 72: 2560–2563.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Hill AB, Barnett BC, McMichael AJ, McGeoch DJ . HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol 1994; 152: 2736–2741.

    CAS  PubMed  Google Scholar 

  38. Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999; 6: 1751–1758.

    Article  CAS  PubMed  Google Scholar 

  39. Wong RJ et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001; 12: 253–265.

    Article  CAS  PubMed  Google Scholar 

  40. Toda M, Martuza RL, Rabkin SD . Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000; 2: 324–329.

    Article  CAS  PubMed  Google Scholar 

  41. Bennett JJ et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001; 233: 819–826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Parker JN et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208–2213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Andreansky S et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5: 121–130.

    Article  CAS  PubMed  Google Scholar 

  44. Dummer R . GVAX (Cell Genesys). Curr Opin Investig Drugs 2001; 2: 844–848.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, B., Robinson, M., Han, ZQ. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10, 292–303 (2003). https://doi.org/10.1038/sj.gt.3301885

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301885

Keywords

This article is cited by

Search

Quick links